Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
Global Amivantamab market was valued at USD 112.4 million in 2024. The market is projected to grow from USD 142.6 million in 2025 to USD 298.1 million by 2032, exhibiting a CAGR of 11.4% during the forecast period.
Amivantamab, marketed under the brand name Rybrevant, is a bispecific antibody that is a cornerstone of targeted oncology. Its unique mechanism of action involves simultaneously targeting the epidermal growth factor receptor (EGFR) and the mesenchymal-epithelial transition (MET) receptor, which are key drivers of tumor growth in certain cancers. Amivantamab is specifically designed as a therapeutic agent and is primarily indicated for the treatment of adult patients with non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy.
The market is experiencing significant growth driven by the increasing prevalence of lung cancer and the critical need for effective treatments for rare mutations like EGFR exon 20 insertions. While the target patient population is niche, the high unmet medical need and the accelerated FDA approval received in 2021 support its market penetration. Furthermore, ongoing clinical trials exploring Amivantamab in combination therapies and for earlier lines of treatment are expected to expand its addressable market. Key developments, such as the submission of a Biologics License Application (BLA) for a subcutaneous formulation to improve patient convenience, signify continuous innovation. The competitive landscape includes pharmaceutical manufacturers and research reagent suppliers like ProteoGenix and Thermo Fisher Scientific, who supply the molecule for research and development purposes.
High Unmet Need in NSCLC
The market for Amivantamab is primarily driven by the significant unmet medical need in metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations. This patient population has historically had limited effective treatment options following platinum-based chemotherapy, creating a clear pathway for adoption of this targeted therapy. The accelerated approval by the FDA in 2021 was a direct response to this urgent need.
Mechanism of Action Advantage
Amivantamab's unique bispecific mechanism, targeting both EGFR and MET receptors, represents a significant driver. This dual-targeting approach can overcome or delay resistance mechanisms that limit the efficacy of earlier-generation EGFR tyrosine kinase inhibitors (TKIs), positioning it as a valuable therapeutic strategy. Its administration as an intravenous infusion within a clinical setting also supports its integration into established cancer care pathways.
The robust clinical data from the CHRYSALIS trial, demonstrating objective response rates, continues to underpin physician confidence and drive utilization.
Furthermore, ongoing clinical trials investigating Amivantamab in earlier lines of therapy and in combination with other agents, such as lazertinib, are expanding its potential market by demonstrating enhanced efficacy, which drives future growth expectations.
MARKET CHALLENGES
Management of Adverse Events
A significant challenge for Amivantamab's market penetration is the management of its unique toxicity profile. Infusion-related reactions are common and require specific monitoring and pre-medication protocols. Additionally, toxicities like rash, paronychia, and potentially serious events such as interstitial lung disease necessitate diligent management by healthcare providers, which can be a barrier to adoption in community oncology settings.
Other Challenges
Competitive Landscape Evolution
The treatment landscape for EGFR exon 20 insertion mutation-positive NSCLC is becoming more competitive with the approval of other agents like mobocertinib. This increases the burden on market access and commercial teams to differentiate Amivantamab's clinical profile and real-world value proposition to payers and physicians.
Reimbursement and Access Hurdles
As a high-cost biologic, securing favorable reimbursement from payers is an ongoing challenge. The need to demonstrate cost-effectiveness relative to other treatments and navigate complex healthcare systems can slow patient access and limit market growth in certain regions.
Limited Target Patient Population
The primary restraint on the Amivantamab market is the relatively small size of its indicated patient population. EGFR exon 20 insertion mutations represent only a small subset of all NSCLC cases, approximately 1-2% in most epidemiological studies. This inherently caps the total addressable market compared to therapies targeting more common driver mutations.
Diagnostic and Testing Barriers
Market growth is also restrained by the need for comprehensive genomic profiling to identify eligible patients. Inconsistent access to next-generation sequencing (NGS) testing, particularly in community hospitals and emerging markets, can lead to under-diagnosis of the specific mutation, preventing eligible patients from receiving the therapy.
Expansion into New Indications
The most significant opportunity for the Amivantamab market lies in label expansion. Ongoing Phase 3 trials, such as PAPILLON (first-line combination therapy) and MARIPOSA (in earlier-stage settings), have the potential to substantially increase the eligible patient population if they lead to new regulatory approvals, moving the drug into larger treatment paradigms.
Geographical Market Expansion
Following its initial approval in the US, gaining regulatory approval and market access in other major regions, particularly Europe and Asia, presents a substantial growth opportunity. Asia-Pacific regions have a higher incidence of EGFR-mutant NSCLC, which could translate into a significant patient pool upon successful market entry.
Development of Subcutaneous Formulation
The development of a subcutaneous formulation of Amivantamab represents a key opportunity to improve patient convenience and reduce the healthcare resource burden associated with lengthy intravenous infusions. This could enhance patient quality of life and potentially lower treatment costs, improving its competitive positioning.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Above 1mg vials represent the leading segment due to their significant utility in clinical and research settings that require larger quantities for comprehensive treatment cycles and extensive experimental protocols. This category is particularly dominant as it caters to the needs of large-scale pharmaceutical production and advanced clinical research projects, where bulk quantities are essential for sustained therapeutic application and robust scientific investigation, reducing the need for frequent reordering and ensuring consistency in research outcomes. |
| By Application |
|
Clinical Testing is the foremost application segment, driven by the critical role of Amivantamab in ongoing clinical trials for treating specific cancer types, particularly non-small cell lung cancer with EGFR exon 20 insertion mutations. The demand is propelled by the necessity for rigorous validation of the drug's efficacy and safety profiles, alongside the expansion of its therapeutic indications through investigative studies. This segment's growth is further supported by increasing investments in personalized medicine and biomarker-driven clinical research. |
| By End User |
|
Pharmaceutical & Biotechnology Companies constitute the dominant end-user segment, as they are the primary entities involved in the development, manufacturing, and commercialization of Amivantamab. Their leadership stems from substantial R&D investments, strategic initiatives to expand drug portfolios in oncology, and the capacity to navigate complex regulatory pathways for drug approval. These companies drive market growth through extensive clinical development programs and efforts to establish Amivantamab as a standard-of-care treatment. |
| By Distribution Channel |
|
Direct Sales is the leading distribution channel, favored for its ability to ensure supply chain integrity, maintain stringent quality control, and facilitate direct technical support and collaboration between manufacturers and end users. This model is critical for a specialized therapeutic agent like Amivantamab, as it allows for better management of cold chain logistics, provides comprehensive product education, and enables a more responsive approach to meeting the specific requirements of clinical and research customers. |
| By Therapeutic Area |
|
Oncology (Non-Small Cell Lung Cancer) is overwhelmingly the dominant therapeutic area for Amivantamab, given its approved indication for treating adult patients with locally advanced or metastatic NSCLC harboring EGFR exon 20 insertion mutations. The segment's leadership is anchored in the significant unmet medical need in this specific patient population, the drug's novel bispecific mechanism of action targeting both EGFR and MET pathways, and the continuous clinical focus on expanding its utility within lung cancer treatment paradigms through combination therapies and earlier lines of treatment. |
An Evolving Market Led by Specialized Biotechnology and Life Sciences Companies
Amivantamab is a bispecific antibody approved for the treatment of non-small cell lung cancer (NSCLC) with specific EGFR mutations. The competitive landscape for Amivantamab itself is distinct from a typical small molecule drug market, as the primary developer and marketer is Janssen Biotech, Inc., a subsidiary of Johnson & Johnson. The market is thus characterized by a highly concentrated structure, with Janssen holding the dominant revenue share. However, the broader competitive environment includes a range of companies involved in the development, manufacturing, and supply of the antibody for research and diagnostic purposes. These players specialize in protein and antibody production, serving the pharmaceutical and life sciences research sectors.
Beyond the primary commercial entity, numerous niche players are significant in supplying Amivantamab for non-therapeutic applications such as clinical testing and academic research. These companies, including specialized biotechnology firms and large life sciences suppliers, focus on producing high-purity research-grade antibodies. They compete on factors such as product quality, purity, specificity, price, and technical support. The market is also influenced by biosimilar development activities, although for a complex biologic like Amivantamab, this remains a longer-term competitive factor. The competitive dynamics are further shaped by ongoing clinical trials investigating Amivantamab in new indications and combination therapies, which could expand the market and attract further interest.
List of Key Amivantamab Companies ProfiledProteoGenix
AntibodySystem SAS
Wuhan Chemstan Biotechnology
Biochempartner
Creative Biolabs
Bio-Techne
Genscript Biotech Corporation
BPS Bioscience, Inc.
Absolute Antibody Ltd.
OriGene Technologies, Inc.
Sino Biological, Inc.
The global Amivantamab market is demonstrating significant growth potential, driven primarily by its application in treating specific oncology indications. The market, which was valued at a substantial figure in 2024, is projected to expand to a significantly larger figure by 2032, with a high compound annual growth rate (CAGR) anticipated during the forecast period. This robust growth trajectory reflects the increasing clinical adoption and the expanding therapeutic reach of the drug. The United States remains the largest national market, estimated at a significant value in 2024. Concurrently, China's market is poised for rapid expansion, projected to reach a substantial figure, indicating a notable shift and growth opportunity within the Asia-Pacific region. The demand is segmented by product quantity, with the 0 - 100ug product segment expected to achieve a considerable market value by 2032, growing at a high CAGR over the coming years.
Other TrendsCompetitive Landscape and Market Concentration
The competitive environment of the Amivantamab market is characterized by the presence of several key manufacturers and suppliers. Leading global companies such as ProteoGenix, Thermo Fisher Scientific, AntibodySystem SAS, Wuhan Chemstan Biotechnology, and Biochempartner are central players. In 2024, the top five players collectively held a dominant share of the global market revenue, indicating a moderately concentrated market structure. These companies are actively involved in the sales, distribution, and ongoing development of Amivantamab, with strategies focusing on scaling production and navigating regulatory landscapes. Recent developments, including potential mergers, acquisitions, and strategic plans from these key players, are critical factors influencing market dynamics, competitive positioning, and future growth trajectories.
Segmentation and Regional Distribution TrendsThe market for Amivantamab is analyzed through multiple segments, including type, application, and geography. By type, the market is divided into 0 - 100ug, 100ug - 1mg, and Above 1mg segments, each catering to different research and clinical needs. The application segments are primarily Pharmaceutics, Clinical Testing, and Others, with the pharmaceutics segment holding a major share due to drug development and manufacturing requirements. Geographically, the market is segmented into North America, Europe, Asia, South America, and the Middle East & Africa. North America, led by the U.S., currently holds the largest market share, but Asia, particularly China and Japan, is expected to exhibit the highest growth rate, driven by increasing investment in healthcare infrastructure and rising prevalence of target diseases. This regional analysis helps in identifying key growth areas and potential blue ocean markets for stakeholders.
Regional Analysis: Amivantamab MarketEurope
Europe represents a significant and growing market for Amivantamab, though adoption varies across member states. The European Medicines Agency (EMA) granted approval, providing a centralized pathway, but national reimbursement processes create a fragmented landscape. Countries with robust healthcare systems, such as Germany and France, have demonstrated faster uptake due to streamlined health technology assessment. The market dynamics are influenced by cost-effectiveness analyses and budget impact considerations, which can lead to access restrictions or managed entry agreements in some countries. Despite these hurdles, there is strong clinical recognition of Amivantamab's value in treating a previously underserved patient population, driving steady market penetration across the region.
Asia-Pacific
The Asia-Pacific region exhibits diverse and rapidly evolving dynamics for the Amivantamab market. Japan and South Korea, with their advanced healthcare systems and rapid regulatory pathways for oncology drugs, are the early adopters. The high prevalence of EGFR mutations in Asian populations creates a substantial underlying patient pool, though specific testing rates for exon 20 insertions are still increasing. Market access in larger emerging economies like China is progressing, heavily influenced by national reimbursement list inclusions and local manufacturing considerations. The region is characterized by a strong focus on value and price negotiations, but the significant unmet medical need ensures growing interest and eventual market expansion.
South America
Market penetration for Amivantamab in South America is in its early stages and faces several challenges. Regulatory approvals are being sought in key countries like Brazil and Argentina, but the process is often lengthier. The primary market dynamic is constrained by healthcare budget limitations, which prioritizes essential medicines over high-cost targeted therapies. Access is largely confined to private healthcare sectors and major academic centers in urban areas. While medical communities are aware of the drug's potential, significant barriers related to diagnostic infrastructure, reimbursement, and affordability currently limit its widespread use, making growth gradual and selective.
Middle East & Africa
The Amivantamab market in the Middle East and Africa is nascent and highly heterogeneous. The Gulf Cooperation Council (GCC) countries, with their larger healthcare budgets, represent the initial entry point, often providing access through leading tertiary care hospitals. In contrast, most African nations have minimal to no access due to extreme cost constraints and underdeveloped oncology care pathways. Market dynamics are defined by extreme disparity; a small number of patients in wealthy nations may receive treatment, while the vast majority in the region remain underserved. Efforts are focused on market education and exploring potential access programs, but widespread adoption is not anticipated in the near term.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and diagnostics manufacturers
Healthcare providers and hospital systems
Contract research and manufacturing organizations
Investors, consultants, and policy makers
-> Global Amivantamab market was valued at USD 112.4 million in 2024 and is projected to reach USD 298.1 million by 2032.
Which key companies operate in Global Amivantamab Market?
-> Key players include ProteoGenix, Thermo Fisher Scientific, AntibodySystem SAS, Wuhan Chemstan Biotechnology, and Biochempartner, among others.
-> The market is expected to grow at a CAGR of 11.4% during the forecast period 2025-2032.
-> Key applications include Pharmaceutics and Clinical Testing, among others.
-> Market is segmented into 0-100ug, 100ug-1mg, and Above 1mg product types.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates